FibroBiologics, Inc. announced the pricing of a $4 million registered direct offering under Nasdaq rules.
The offering includes the issuance and sale of 3,540,000 shares of common stock and pre-funded warrants to purchase 8,570,203 shares.
The purchase price for shares or prefunded warrants will be paid in sovereign-issued .9999 fine gold coins valued at $4,069.18 per oz.
Issuance Details
3,540,000 shares of common stock and pre-funded warrants to purchase 8,570,203 shares were issued in the offering.
Payment Method
The purchase price for shares or prefunded warrants will be paid in gold coins valued at $4,069.18 per oz.
Utilization of Proceeds
Net proceeds from the offering will be used for general corporate purposes and debt satisfaction.
- The offering is expected to strengthen FibroBiologics' capital structure and provide flexibility for future growth initiatives.
- The company may receive additional gross proceeds of $4.0 million if holders of unregistered warrants exercise them following Stockholder Approval.
FibroBiologics is strategically utilizing the offering proceeds to enhance its financial position and support corporate objectives, setting a foundation for future growth and innovation in the biotechnology sector.